Louise Frederika Kooij
CIK: 0002004379
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NewAmsterdam Pharma Co N.V.
Discretionary Trading P&L
Holdings
Transaction History (45 total)
- Jul 20, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct2.9K shares at avg. $31.71$92K - Jul 20, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct25K shares at avg. $11.90$298K - Jul 20, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct80K shares at avg. $11.17$894K - Jul 20, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct70.2K shares at avg. $29.96$2.1M - Jul 20, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct31.9K shares at avg. $31.05$990K - Jun 22, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct15K shares at avg. $11.90$179K - Jun 22, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct300 shares at avg. $30.73$9K - Jun 22, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct25K shares at avg. $10.90$273K - Jun 22, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct39.7K shares at avg. $30.20$1.2M - May 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct65K shares at avg. $35.69$2.3M - May 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct5K shares at avg. $10.90$55K - May 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct60K shares at avg. $10.00$600K - Jan 28, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct32.6K shares at avg. $10.90$355K - Jan 28, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct32.6K shares at avg. $31.80$1.0M - Jan 27, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct39.8K shares at avg. $32.62$1.3M - Jan 27, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct39.8K shares at avg. $10.90$434K - Jan 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct34.1K shares at avg. $32.77$1.1M - Jan 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct34.4K shares at avg. $10.90$375K - Jan 26, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct309 shares at avg. $33.45$10K - Jan 23, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct12.8K shares at avg. $34.37$439K - Jan 23, 2026NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct38.2K shares at avg. $10.90$416K - Jan 23, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct25.4K shares at avg. $33.44$850K - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct12K shares- - Jan 5, 2026NAMS
NewAmsterdam Pharma Co N.V.
Sale(S)Direct2.6K shares at avg. $33.25$88K - Dec 26, 2025NAMS
NewAmsterdam Pharma Co N.V.
Exercise(M)Direct38.9K shares at avg. $10.00$389K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 20, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 2,915 | $31.71 | $92,435 | Direct |
| Jul 20, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 25,000 | $11.90 | $297,500 | Direct |
| Jul 20, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 80,000 | $11.17 | $893,600 | Direct |
| Jul 20, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 70,200 | $29.96 | $2,103,192 | Direct |
| Jul 20, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 31,885 | $31.05 | $990,029 | Direct |
| Jun 22, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 15,000 | $11.90 | $178,500 | Direct |
| Jun 22, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 300 | $30.73 | $9,219 | Direct |
| Jun 22, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 25,000 | $10.90 | $272,500 | Direct |
| Jun 22, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 39,700 | $30.20 | $1,198,940 | Direct |
| May 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 65,000 | $35.69 | $2,319,850 | Direct |
| May 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 5,000 | $10.90 | $54,500 | Direct |
| May 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 60,000 | $10.00 | $600,000 | Direct |
| Jan 28, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 32,612 | $10.90 | $355,471 | Direct |
| Jan 28, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 32,612 | $31.80 | $1,037,062 | Direct |
| Jan 27, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 39,816 | $32.62 | $1,298,798 | Direct |
| Jan 27, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 39,816 | $10.90 | $433,994 | Direct |
| Jan 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 34,091 | $32.77 | $1,117,162 | Direct |
| Jan 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 34,400 | $10.90 | $374,960 | Direct |
| Jan 26, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 309 | $33.45 | $10,336 | Direct |
| Jan 23, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 12,767 | $34.37 | $438,802 | Direct |
| Jan 23, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 38,172 | $10.90 | $416,075 | Direct |
| Jan 23, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 25,405 | $33.44 | $849,543 | Direct |
| Jan 7, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 12,000 | - | $0 | Direct |
| Jan 5, 2026 | NAMS NewAmsterdam Pharma Co N.V. | Sale(S) | 2,647 | $33.25 | $88,013 | Direct |
| Dec 26, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Exercise(M) | 38,872 | $10.00 | $388,720 | Direct |
1-25 of 45 transactions
About Kooij Louise Frederika
Kooij Louise Frederika (SEC CIK 0002004379) files insider reports with the SEC as Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS).
Signal8 holds 16 ownership filings by Kooij Louise Frederika, all Form 4s, filed between Oct 1, 2024 and Jul 22, 2026. Those filings report 45 transactions, from Sep 27, 2024 to Jul 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kooij Louise Frederika's filings is in NAARDEN.
Recent filings by Kooij Louise Frederika
- Jul 20, 2026: Open-market sale of NAMS shares (Form 4, code S).
- Jul 20, 2026: Option exercises of NAMS shares (2 lines, Form 4, code M).
- Jul 20, 2026: Open-market sales of NAMS shares (2 lines, Form 4, code S).
- Jun 22, 2026: Option exercise of NAMS shares (Form 4, code M).
- Jun 22, 2026: Open-market sale of NAMS shares (Form 4, code S).
Other insiders filing for NewAmsterdam Pharma Co N.V. (NAMS)
- Kastelein Johannes Jacob Pieter, Chief Scientific Officer
- Davidson Michael H., Chief Executive Officer
- Smither John W, Director
- Gunning Robert William, Vice President, Controller
- LANGE LOUIS G, Director
- Somaiya Mayur Ian, Chief Financial Officer